Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2020-07-16
Target enrollment:
Participant gender:
Summary
This randomized phase I trial is studying the side effects and the best dose of selumetinib
when given together with paclitaxel as a second line therapy in treating patients with stage
IIIB-IV non-small cell lung cancer (NSCLC). Selumetinib may stop or slow the growth of tumor
cells by blocking a protein called mitogen-activated protein kinase (MEK) that is needed for
cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving selumetinib together with paclitaxel may kill more tumor
cells.
Phase:
Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
AstraZeneca National Cancer Institute (NCI) Oregon Health and Science University